Amlodipine/valsartan - Misplaced Pages

(Redirected from Amlodipine/valsartan/hydrochlorothiazide) Antihypertensive medication

Pharmaceutical compound

Amlodipine/valsartan
Combination of


Amlodipine	Calcium channel blocker
Valsartan	Angiotensin II receptor antagonist
Clinical data
Trade names	Exforge, Copalia, Dafiro
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Amlodipine and valsartan
Pregnancy category	AU: D
Routes of administration	By mouth
ATC code	C09DB01 (WHO)
Legal status
Legal status	US: ℞-only EU: Rx-only
Identifiers
CAS Number	1190398-97-0
PubChem CID	11354874
ChemSpider	13092186
KEGG	D09745 with HCTZ: D10286
CompTox Dashboard (EPA)	DTXSID10180185
(verify)

Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist. This combination is usually well tolerated and effective for the reduction of blood pressure.

The combination was approved for medical use in the European Union in January 2007, and in the United States in June 2007.

The combination is also available with hydrochlorothiazide. It was approved for medical use in the United States in April 2009, and in the European Union in November 2009.

References

"Amlodipine / valsartan (Exforge) Use During Pregnancy". Drugs.com. 11 July 2019. Retrieved 13 February 2020.
"Exforge- amlodipine besylate and valsartan tablet, film coated". DailyMed. 12 June 2019. Retrieved 12 February 2020.
^ "Exforge EPAR". European Medicines Agency (EMA). 17 January 2007. Retrieved 26 August 2024.
"Copalia EPAR". European Medicines Agency (EMA). 16 January 2007. Retrieved 26 August 2024.
"Dafiro EPAR". European Medicines Agency (EMA). 16 January 2007. Retrieved 26 August 2024.
"Valsartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
Eckert S, Freytag SB, Müller A, Klebs SH (September 2013). "Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors". Blood Pressure. 22 (sup1): 11–21. doi:10.3109/08037051.2013.793891. PMID 23713686. S2CID 25814898.
"Drug Approval Package: Exforge (amlodipine and valsartan) NDA #021990". U.S. Food and Drug Administration (FDA). 3 October 2008. Retrieved 19 September 2021.
"Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated". DailyMed. Retrieved 12 February 2020.
"Amlodipine, Valsartan, and Hydrochlorothiazide". Drugs.com.
"Drug Approval Package: Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets NDA #022314". U.S. Food and Drug Administration (FDA). 2 September 2009. Retrieved 19 September 2021.
"Exforge HCT EPAR". European Medicines Agency (EMA). 16 October 2009. Retrieved 26 August 2024.
"Copalia HCT EPAR". European Medicines Agency (EMA). 4 November 2009. Retrieved 26 August 2024.
"Dafiro HCT EPAR". European Medicines Agency (EMA). 4 November 2009. Retrieved 26 August 2024.

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing: Enalapril (+lercanidipine, +nitrendipine) Benazepril (+amlodipine, +pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+amlodipine, +bisoprolol, +indapamide, +amlodipine and indapamide, +bisoprolol and amlodipine, +bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine, +amlodipine and HCT, +bisoprolol, +felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine, +amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine, +amlodipine and HCT, +HCT) Losartan (+amlodipine, +HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan Telmisartan (+amlodipine, +amlodipine and HCT, +HCT) Valsartan (+aliskiren, +amlodipine, +amlodipine and HCT, +HCT, +lercanidipine, +nebivolol, +sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
WHO-EM Withdrawn from market Clinical trials: Phase III Never to phase III

v t e Angiotensin receptor modulators
ATRTooltip Angiotensin receptor	Agonists: Angiotensin II Angiotensin III Angiotensin IV L-163,491 Saralasin Antagonists: Abitesartan Azilsartan Candesartan Elisartan Embusartan Eprosartan EXP-3174 Fimasartan Forasartan Irbesartan Losartan Milfasartan Olmesartan Olodanrigan PD123319 Pomisartan Pratosartan Ripisartan Saprisartan Sparsentan Tasosartan Telmisartan Valsartan Zolasartan ACE inhibitors: Alacepril Benazepril Captopril Cilazapril Delapril Enalapril Enalaprilat Fosinopril Gemopatrilat Imidapril Lisinopril Moexipril Omapatrilat Perindopril Quinapril Quinaprilat Ramipril Rentiapril Rescinnamine Spirapril Spiraprilat Temocapril Trandolapril Zofenopril Zofenoprilat Renin inhibitors: Aliskiren Ciprokiren Ditekiren Enalkiren Imarikiren Pepstatin Remikiren Terlakiren Zankiren Propeptides: Angiotensinogen Angiotensin I
Combinations:	Amlodipine/valsartan Olmesartan/amlodipine Olmesartan/amlodipine/hydrochlorothiazide Valsartan/hydrochlorothiazide Valsartan/hydrochlorothiazide/amlodipine

Angiotensin receptor modulators

ATRTooltip Angiotensin receptor

Propeptides: Angiotensinogen
Angiotensin I

Combinations:

Portal:

Medicine

This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: